Trial Profile
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 21 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 21 Jul 2023 Planned primary completion date changed from 31 May 2023 to 31 May 2024.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology